Literature DB >> 9516848

The prognostic value of MDR1 gene expression in primary untreated neuroblastoma.

M Haber1, S B Bordow, P S Haber, G M Marshall, B W Stewart, M D Norris.   

Abstract

The contribution of MDR1 gene expression to the biology of childhood neuroblastoma is unclear. To clarify the role of MDR1 in this malignancy, we examined the relationship between MDR1 expression and patient outcome in subsets of 60 primary untreated neuroblastomas for which MYCN gene copy number and expression of the multidrug resistance-associated-protein (MRP) gene had been previously characterised. In contrast to MRP gene expression, MDR1 expression was lower in tumours with MYCN gene amplification compared with those without amplification. Strong correlations between MDR1 and MRP gene expression, and between MDR1 and MYCN gene expression, were observed in tumours lacking MYCN gene amplification (P < 0.0005). In these single-copy tumours, very high MDR1 gene expression was significantly associated with poor outcome (P < 0.05). Very high MDR1 expression was also strongly predictive of poor outcome in older children (P < 0.0001), but not in infants. These findings suggest a clinical role for the MDR1 gene in specific subgroups of primary neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9516848     DOI: 10.1016/s0959-8049(97)00229-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  21 in total

Review 1.  [Neuroblastoma].

Authors:  Victoria Castel; Adela Cañete; Rosa Noguera; Samuel Navarro; Silvestre Oltra
Journal:  Clin Transl Oncol       Date:  2005-04       Impact factor: 3.405

2.  Knowing your ABCCs: novel functions of ABCC transporters.

Authors:  Garrett M Brodeur
Journal:  J Natl Cancer Inst       Date:  2011-07-28       Impact factor: 13.506

3.  β-arrestin 2 is associated with multidrug resistance in breast cancer cells through regulating MDR1 gene expression.

Authors:  Xuanxuan Jing; Hui Zhang; Jing Hu; Peng Su; Wei Zhang; Ming Jia; Hongxia Cheng; Weiwei Li; Gengyin Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

4.  Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt/β-catenin pathway.

Authors:  Z-M Zhang; J-F Wu; Q-C Luo; Q-F Liu; Q-W Wu; G-D Ye; H-Q She; B-A Li
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

Review 5.  Gastric carcinogenesis and the cancer stem cell hypothesis.

Authors:  Yoshiro Saikawa; Kazumasa Fukuda; Tsunehiro Takahashi; Rieko Nakamura; Hiroya Takeuchi; Yuko Kitagawa
Journal:  Gastric Cancer       Date:  2010-04-07       Impact factor: 7.370

6.  A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.

Authors:  Wayne L Furman; Lisa M McGregor; M Beth McCarville; Mihaela Onciu; Andrew M Davidoff; Sandy Kovach; Dana Hawkins; Valerie McPherson; Peter J Houghton; Catherine A Billups; Jianrong Wu; Clinton F Stewart; Victor M Santana
Journal:  Invest New Drugs       Date:  2011-07-28       Impact factor: 3.850

Review 7.  Sphingolipids in neuroblastoma: their role in drug resistance mechanisms.

Authors:  Hannie Sietsma; Anne Jan Dijkhuis; Willem Kamps; Jan Willem Kok
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

8.  A distinct "side population" of cells with high drug efflux capacity in human tumor cells.

Authors:  C Hirschmann-Jax; A E Foster; G G Wulf; J G Nuchtern; T W Jax; U Gobel; M A Goodell; M K Brenner
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-20       Impact factor: 11.205

9.  Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs.

Authors:  Nadine Löschmann; Martin Michaelis; Florian Rothweiler; Richard Zehner; Jaroslav Cinatl; Yvonne Voges; Mohsen Sharifi; Kristoffer Riecken; Jochen Meyer; Andreas von Deimling; Iduna Fichtner; Taravat Ghafourian; Frank Westermann; Jindrich Cinatl
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

10.  The translocator protein (TSPO) ligand PK11195 induces apoptosis and cell cycle arrest and sensitizes to chemotherapy treatment in pre- and post-relapse neuroblastoma cell lines.

Authors:  Maria C Mendonça-Torres; Stephen S Roberts
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.